Darmiyan, Inc.

Darmiyan, Inc. is a neuroscience-driven AI and medical imaging software company developing diagnostic tools for early detection and monitoring of neurodegenerative diseases, specifically Alzheimer's disease and dementia. The company's core technology leverages over four decades of pioneering brain research combined with advanced machine learning and medical image processing to analyze cellular-level changes in brain MRI scans. BrainSee, Darmiyan's flagship FDA De Novo-approved software, utilizes proprietary algorithms to quantify microscopic tissue architecture changes (voxel-level analysis) within standard clinical-grade MRI scans, enabling non-invasive early disease detection and patient-specific monitoring of therapeutic responses. The company targets three primary markets: early Alzheimer's detection in at-risk populations, objective measurement of patient response to interventions, and biomarker development for pharmaceutical drug development programs. Darmiyan's technology is designed around four core pillars: high diagnostic accuracy, non-invasiveness, seamless integration with existing MRI infrastructure, and global accessibility. The platform operates without requiring specialized imaging hardware, positioning it for broad adoption across healthcare settings. FDA Breakthrough Designation was granted to BrainSee for its potential to improve treatment of Alzheimer's disease. Third-party clinical validation has been completed in the US and Canada by independent research investigators. The company serves healthcare providers, pharmaceutical development teams, academic medical centers, and clinical research organizations pursuing precision brain health screening and monitoring solutions.